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Background: Mutant proinsulin-G(B23)V is 
defective in formation of native disulfide bonds. 
Results: Overexpression of Ero1α partially 
rescues secretion of mutant proinsulin-G(B23)V.  
Conclusion:  Enhanced ER oxidation is of 
potential benefit to proinsulin folding.   
Significance:  Diseases involving proinsulin 
misfolding might be ameliorated by techniques 
augmenting protein oxidation in the ER of 
pancreatic β-cells.   
SUMMARY 
Upon chronic upregulation of proinsulin 
synthesis, misfolded proinsulin can 
accumulate in the endoplasmic reticulum 
(ER) of pancreatic β-cells, promoting ER 
stress and type 2 diabetes mellitus.  In 
Mutant Ins-gene induced Diabetes of Youth 
(MIDY), misfolded mutant proinsulin 
impairs ER exit of co-expressed wild-type 
proinsulin, limiting insulin production and 
leading to eventual β-cell death.  In this 
study, we have investigated the hypothesis 
that increased expression of ER 
oxidoreductin 1-alpha (Ero1α) — despite its 
established role in the generation of H2O2 — 
might nevertheless be beneficial in limiting 
proinsulin misfolding and its adverse 
downstream consequences.  Increased Ero1α 
expression is effective in promoting wildtype 
proinsulin export from cells co-expressing 
misfolded mutant proinsulin.  In addition, we 
find that upon increased Ero1α expression, 
some of the MIDY mutants themselves are 
directly rescued from ER retention. 
Secretory rescue of proinsulin-G(B23)V is 
correlated with improved oxidative folding of 
mutant proinsulin.  Indeed, using three 
different variants of Ero1α, we find that 
expression of either wildtype or an Ero1α 
variant lacking regulatory disulfides can 
rescue mutant proinsulin-G(B23)V, in 
parallel with its ability to provide an 
oxidizing environment in the ER lumen — 
whereas beneficial effects were less apparent 
for a redox-inactive form of Ero1.  Increased 
expression of protein disulfide isomerase 
(PDI) antagonizes the rescue provided by 
oxidatively active Ero1.  Importantly, ER 
stress induced by misfolded proinsulin was 
limited by increased expression of Ero1α, 
suggesting that enhancing the oxidative 
folding of proinsulin may be a viable 
therapeutic strategy in the treatment of type 2 
diabetes. 
The single-chain insulin precursor, 
proinsulin, is the principal protein synthesized in 
pancreatic β-cells and consists sequentially of 
the insulin B-chain, C-peptide with flanking 
cleavage sites, and insulin A-chain.  Nascent  
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proinsulin must fold properly including the 
formation of three native disulfide bridges (B7-
A7, B19-A20 and A6-A11) for efficient export 
from the endoplasmic reticulum (ER) and 
delivery to secretory granules for processing and 
exocytosis of mature insulin (1).  Despite the 
central biomedial importance of this process, the 
specific enzymes involved in the oxidative 
folding of proinsulin remain poorly understood 
(2).  The present study focuses on the role of one 
such enzyme, Ero1α.   
Our studies were motivated by the role 
of proinsulin misfolding in β-cell dysfunction. 
Under conditions of increased synthesis, 
proinsulin is susceptible to increased misfolding 
involving the mispairing of cysteines to form 
non-native disulfide bonds (3,4).  Accumulation 
of misfolded proinsulin in the ER triggers a state 
known as ER stress — leading to activation of 
unfolded protein response pathways that may 
culminate in apoptosis (5) with ultimate loss of 
pancreatic β-cell mass (6) and type 2 diabetes 
(7).  Indeed, misfolded proinsulin is an 
established cause of autosomal dominant 
diabetes in the syndrome of Mutant Ins gene-
induced Diabetes of Youth (MIDY) (8).  The 
mutant proinsulin molecules are retained in the 
ER due to a defect in their folding (9); 
moreover, misfolded mutant proinsulin 
molecules exert a dominant-negative effect on 
the export of co-expressed wild-type molecules 
through direct association (8,10,11), leading to 
ER stress and eventual β-cell death (12).   
In recent years, increasing attention has 
been paid to the role of ER Oxidoreductin-1 
(Ero1) in promoting the oxidative folding of 
proinsulin in the ER (13,14).  Mammals express 
two isoforms of Ero1 (α and β); both are ER 
luminal flavoproteins that couple reduction of 
molecular oxygen with the oxidation of ER 
oxidoreductases such as protein disulfide 
isomerase (PDI) (15).  In turn, the ER 
oxidoreductases can shuttle disulfide bonds to 
substrates to catalyze the folding of newly-
synthesized secretory proteins (16,17), such as 
proinsulin (2).  Among other pathways, Ero1 is 
the best-known source of disulfide bonds in the 
ER lumen (18).  Since Ero1 deficiency impairs 
proinsulin maturation and predisposes to insulin-
deficient diabetes (13), it occurred to us that 
improved proinsulin oxidative folding may 
provide a novel approach to ameliorating insulin 
production, especially under states of ER stress 
in which misfolded proinsulin may block export 
of bystander proinsulin molecules (19). 
Propelled by the hypothesis that improvement of 
proinsulin folding kinetics may overcome ER 
retention of both mutant and WT molecules, in 
this study we have examined the effect(s) of 
increased Ero1α expression on misfolded 
proinsulin in the ER.  The results suggest that 
manipulating the β-cell ER proteome may 
provide a therapeutic window though which 
proinsulin misfolding may be ameliorated.   
EXPERIMENTAL PROCEDURES 
  Cell Culture and Transfection - 293T cells 
were cultured in DMEM plus 10% fetal bovine 
serum and penicillin/streptomycin (100 U/mL; 
100 µg/mL).  INS1E cells were cultured in 
RPMI 1640 medium supplemented with 10% 
fetal bovine serum, 1 mM pyruvate, 10 mM 
HEPES, penicillin/streptomycin (as above) and 
50 µM 2-mercaptoethanol.  Flp-In T-Rex 293 
cells were stably transfected with empty vector, 
Ero1α-WT, or Ero1α-Active, as previously 
described (20), were maintained in MEM 
(Sigma, M4526) supplemented with 10% fetal 
bovine serum, penicillin/streptomycin (as 
above), 1x GlutaMAX (Gibco), 7.5 µg/ml 
blasticidin, and 50 µg/ml hygromycin.  For 
induction of gene expression, cells were 
incubated in complete media containing 1 ug/ml 
doxycycline for 24 h.  
Proinsulin variants were expressed in 
pcDNA3.1 (Invitrogen) or pTarget (Promega), 
Ero1α variants were expressed in 
pcDNA5/FRT/TO (Invitrogen), roGFP-iE(ER) 
was expressed in pcDNA3.1, and PDI-flag was 
expressed in pcDNA3.1/V5-His TOPO TA.  All 
plasmids have been previously described except 
Ero1α-C94A, C99A, C104A, C131A, C394A, 
C397A (“Ero1α-Hex”) that was generated with 
the Quikchange Site-Directed Mutagenesis Kit 
(Agilent).  Plasmids were transfected using 
Lipofectamine 2000 (Invitrogen) for 293T cells 
or Metafectene Pro (Biontex) for INS1E and 
Flp-In T-Rex 293 cells.  Total plasmid DNA 
amount was held constant within each 
experiment by inclusion of empty vector.   
  Proinsulin Measurements and Western Blotting 
- For secretion experiments, 24 - 48 h post-
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transfection, culture media was changed and 
collected overnight.  Cells were lysed in RIPA 
buffer (0.1 M NaCl, 0.2 % deoxycholate, 25 mM 
Tris-pH 7.4, 1% Triton X-100, 0.1% SDS, 10 
mM EDTA pH 8.0, and a proteinase inhibitor 
cocktail).  Proinsulin was measured by rat 
insulin radioimmunoassay (RIA, Millipore) that 
recognizes insulins and proinsulins of multiple 
species, or human proinsulin-specific RIA 
(Millipore), normalized to total cell protein 
measured by BCA assay (Pierce).  For 
immunoblotting, proteins (10 µg/lane) were 
resolved by SDS-PAGE on 4-12% acrylamide 
gradient gels (‘NuPAGE’), electrotransferred to 
nitrocellulose, and immunoblotted with either 
anti-Ero1α (Santa Cruz), anti-Myc (Immunology 
Consultant Laboratories), or anti-α-Tubulin as a 
loading control (Sigma).  Horseradish 
peroxidase-conjugated secondary antibodies 
were from Jackson ImmunoResearch, with 
proteins visualized by ECL (Millipore).   
  Metabolic labeling - At 48 h post-transfection, 
cells were starved in DMEM lacking cysteine 
and methionine for 30 min.  After pulse-labeling 
with 35S labeled cysteine and methionine as 
indicated, cells were lysed in RIPA buffer 
containing 2 mM N-ethylmaleimide (NEM) and 
immunoprecipitated with anti-Myc or anti-
insulin antibodies and protein A-agarose.  
Immunoprecipitates were separated by reducing 
or non-reducing tris-tricine-urea-SDS-PAGE 
and analyzed by autoradiography as previously 
described (21).  For both immunoblotting and 
metabolic labeling, gel bands were quantified 
using ImageQuant software.   
  ER Oxidation - Oxidation of the ER in Flp-In 
TRex 293 cells using the HyPerER sensor, and in 
INS1E cells using Grx1-roGFP1-iEER, was 
measured as previously described (22,23).  
Briefly, Flp-In TRex 293 cells were stably 
transfected with plasmid expressing the HyPerER 
sensor (24) as previously described (23).  After 
induction of expression of Ero1α variants with 1 
µg/mL doxycycline for 24 h, fluorescence 
spectra were obtained at steady state or in the 
presence of 10 mM DTT or 100 µM H2O2, with 
excitation ranging from 410-510 nm and 
emission at 535 nm.  The ratios of fluorescence 
emission intensities upon excitation at 500 nm 
and at 420 nm from independent experiments 
were logarithmically transformed and fitted to a 
linear model using a batch specific offset value 
with calculation as previously described (23).  
INS1E, cells were co-transfected with Ero1α 
variant or empty vector and Grx1-roGFP1-iEER, 
washed and incubated in PBS containing 20 mM 
NEM on ice for 20 min, and lysed on ice for 1 h 
in 100 mM NaPO4 pH 8, containing 1% Triton-
X-100 and 200 µM 
phenylmethylsulfonylfluoride.  After removal of 
insoluble cell debris by centrifugation, the 
supernatant was immunoprecipitated using 
NHS-activated agarose (Thermo Scientific) 
decorated with anti-GFP.  Samples were 
separated by nonreducing SDS-PAGE and 
immunoblotted using anti-HA antibodies.  Blots 
were analyzed densitometrically to determine 
the percentage of oxidized sensor (22).   
  BiP-Luciferase Measurement - 24 h post-
transfection with proinsulin, Ero1α, and BiP 
promoter-driven luciferase expression plasmids, 
cells were split into 2 separate wells.  One well 
was lysed in Passive Lysis Buffer (Promega) and 
luciferase was measured using the Dual-Light 
Kit (Promega): the other was lysed in Buffer 
RLT and homogenized using QIAShredder 
(Qiagen).  RNA was isolated using RNeasy 
(Qiagen); cDNA was generated using the 
Superscript III First Strand Synthesis Kit 
(Invitrogen).  RT-qPCR was performed using 
Power SYBR Green (Invitrogen) with human 
proinsulin specific primers: 5’-
CGCAGCCTTTGTGAACCAAC-3’ (Forward) 
and 5’- TGGGTGTGTAGAAGAAGCCTC-3’ 
(Reverse).  Luciferase activity was normalized 
directly to human proinsulin mRNA levels.   
  Statistical Analysis -  Statistical analyses were 
conducted using GraphPad Prism software.  
Data are presented as mean ± SEM, unless 
otherwise noted.  Two-tailed Student’s t-test was 
used to assess statistical significance, with a 
threshold for significance of p < 0.05.  For 
analysis of HyPerER data, linear regression, 95% 
confidence intervals, and p-values were all 
calculated using Microsoft Excel.   
 
RESULTS 
  Ero1 Rescues Wildtype Proinsulin in the 
Presence of MIDY Mutants - MIDY mutations 
cause proinsulin to act as a dominant-negative 
mutant that inhibits WT insulin production (6,9-
11); an effect that may be reversed upon 
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increased expression of Ero1β and even more by 
Ero1α (19).  To examine more closely the effect 
of increased Ero1 expression on this dominant-
negative behavior, we co-transfected the INS1E 
β-cell line with wild-type human proinsulin 
tagged with a myc-epitope (hPro-CpepMyc) plus 
either WT or mutant mouse proinsulin (mPro).  
As previously reported (8), mouse mutant 
proinsulins C(A7)Y or G(B23)V each impaired 
secretion of co-expressed human WT proinsulin, 
as measured by human proinsulin-specific 
radioimmunoassay (Fig. 1).  However, co-
transfection of Ero1α in β-cells rescued 
secretion of WT proinsulin in the presence of 
mutant proinsulins C(A7)Y or G(B23)V (Fig. 1).   
  Ero1 Directly Rescues A Selective Subset of 
MIDY Mutants, with Effects that are Additive to 
Secretory Rescue by Wildtype Proinsulin - We 
wished to determine if prevention of dominant-
negative behavior involves primarily Ero1 
activity on WT proinsulin, or if it might also be 
attributed to direct effects on mutant proinsulin 
molecules.  With this in mind, we examined the 
effect of increased Ero1α expression on the 
secretion of a variety of MIDY mutant 
proinsulins expressed in 293T cells in which WT 
proinsulin is not co-expressed.  Remarkably, 
several proinsulin mutants including G(B8)S and 
G(B23)V were rescued upon increased 
expression of Ero1α, while others including 
L(B11)P and C(A7)Y could not be rescued (Fig. 
2 lanes 6 and 10 versus lanes 7 and 14 ).  When 
examining the different transiently transfected 
samples, it was clear that the greatest magnitude 
of secretion rescue did not correlate with 
samples bearing the highest levels of Ero1α 
protein; rather, these results suggest that 
increased Ero1α can augment secretion of a 
subset of MIDY mutants in a manner that 
depends primarily upon the precise mutation 
perturbing proinsulin folding.   
 Wildtype proinsulin can dimerize with 
mutant proinsulin (25), and wildtype proinsulin 
can also augment secretion of a similar subset of 
misfolded MIDY mutants (26).  We wished to 
pursue whether Ero1-mediated secretion rescue 
phenocopied the effects of WT proinsulin; with 
this in mind, we examined the effects of these 
treatments individually, or together, on mutant 
proinsulin secretion. In the presence of WT 
proinsulin, we observed a modest (~threefold) 
increase in secretion of the MIDY mutant 
proinsulin-G(B23)V (Fig. 3A, second bar).  
Upon increased Ero1α expression, we observed 
a much greater increase in proinsulin-G(B23)V 
secretion (Fig. 3A, third bar).  When the two 
treatments were combined, the resulting increase 
in proinsulin-G(B23)V secretion appeared 
additive (fourth bar).  Thus, although secretory 
rescue may be achieved for the same mutants by 
both methods, the data imply that Ero1 and WT 
proinsulin may rescue misfolded proinsulin by 
distinct mechanisms.   
  Ero1α Enhances Folding of Mutant Proinsulin-
G(B23) - To examine how increased expression 
of Ero1 impacts on proinsulin-G(B23)V folding, 
we co-transfected 293T cells with 
hProG(B23)V-CpepMyc plus Ero1α or empty 
vector, and metabolically labeled newly-
synthesized proteins with 35S-amino acids.  
Immunoprecipitated proinsulin was then 
analyzed by nonreducing Tris-Tricine-Urea-
SDS-PAGE.  Proinsulin-WT can be resolved 
into differentially-migrating bands (Fig. 3B, 
lower panel), the fastest of which comprises the 
majority and represents native proinsulin; the 
slowest represents fully reduced proinsulin, and 
intermediate bands represent incompletely or 
improperly folded proinsulin disulfide isomers 
(3).  Under reducing conditions, all 
oxidized/partially-oxidized proinsulin bands 
migrate as a single reduced band (Fig. 3B, 
bottom panel).  Under nonreducing conditions, 
the fraction of proinsulin-G(B23)V that achieved 
the native disulfide-bonded form was less than 
10% of all molecules (Fig. 3B lane 2).  
Importantly, when Ero1α was co-transfected, the 
fraction of proinsulin-G(B23)V achieving a 
native-like mobility was notably increased (Fig. 
3B lane 3), although the fraction of non-native 
isoforms still remained greater than that seen for 
WT proinsulin (lane 1).  Moreover, upon pulse-
labeling and 2 h chase, much of the secreted 
proinsulin-G(B23)V from cell co-transfected 
with Ero1α migrated under nonreducing 
conditions like WT proinsulin — comparable in 
mobility to the native-like intracellular species 
(Fig. 3C).  This result contrasts with that from 
control cells co-transfected with empty vector, in 
which no bands of secreted proinsulin-G(B23)V 
could be detected (not shown).   
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In 293T cells, co-transfection with 
Ero1α plasmid typically caused the synthesis of 
labeled proinsulin-G(B23)V to appear 
diminished (Fig. 3B lane 3 reduced sample) – 
this was less evident in β-cells and was not 
correlated with increased ER stress (see below), 
but may reflect competition between CMV 
promoters from different plasmids.  However, 
decreased synthesis of proinsulin-G(B23)V in 
293T cells cannot readily explain its increased 
secretion from the same cells (Figs. 2, 3).  
Rather, secretory rescue by Ero1α is correlated 
with increased oxidation of proinsulin-G(B23)V.   
 Secretion Rescue Activity of Mutant Proinsulin-
G(B23)V by Ero1α Variants ± PDI -  Oxidase 
activity of Ero1α, involving the communicating 
C394-C397 and C94-C99 active site disulfides, 
is negatively regulated by alternative disulfide 
linkages involving Cys residues at positions 104 
and 131 (20,27).  We utilized a plasmid 
expressing Ero1αMyc6His with the regulatory 
Cys residues mutated to Ala; this construct 
(herein called Ero1α-Active) has been shown to 
have increased activity compared to Ero1α-WT 
(27,28).  We also mutated the four active sites 
plus the two regulatory Cys residues in a 
construct called Ero1α-Hex (Fig. 4A), which 
lacks the ability to generate disulfide bonds.  As 
measured by immunoblotting, unlike WT 
proinsulin (Fig. 4B lane 1), a negligible amount 
of proinsulin-G(B23)V could be secreted from 
cells to medium (Fig. 4B lane 2).  However, co-
expression of WT Ero1α or Ero1α-Active 
markedly increased overall proinsulin-G(B23)V 
secretion (Fig. 4B lanes 3 and 5).  By contrast, 
enhanced proinsulin-G(B23)V secretion was 
only minimally affected by co-expression of the 
Ero1α-Hex mutant (Fig. 4B lane 4) — although 
when considered as a fraction of total (cell + 
medium) even Ero1α-Hex promoted a small but 
statistically significant increase in fractional 
secretion of mutant proinsulin (Fig. 4C).   
 To determine if rescue of mutant 
proinsulin by Ero1 correlated with increased 
oxidation of the ER lumen, ER redox state and 
proinsulin secretion was examined in two cell 
lines: Flp-In T-Rex 293 cells with inducible 
expression of either Ero1α-WT or Ero1α-Active, 
and transiently transfected INS1E cells.  For 
Flp-In T-Rex 293 cells, ER redox poise upon 
doxycycline (DOX)-induced expression of Ero1 
variants was measured by the HyPerER sensor 
that directly reacts with H2O2 and can also be 
oxidized via ER luminal oxidative folding 
machinery (23). Induced expression of both 
Ero1α-WT and Ero1α-Active increased the ER 
luminal oxidation of the HyPerER reporter; 
however, the effect for Ero1α-WT did not 
achieve statistical significance (p = 0.058), 
whereas significance was achieved for Ero1α-
Active (Fig. 5A).  In parallel with the increased 
oxidative environment of the ER lumen, mutant 
hProG(B23)V-CpepMyc secretion was 
augmented (Fig. 5B).   
Because transient co-expression of the 
HyPerER sensor and Ero1α variants is unsuitable 
for subsequent spectral analysis (23), in the 
INS1E β-cell line we employed the ER-targeted, 
glutathione reactive redox-sensitive green 
fluorescent protein known as Grx1-roGFP1-
iEER, the oxidation state of which can be 
monitored by mobility shift upon nonreducing 
SDS-PAGE (22).  As expected, ectopic 
expression of both Ero1α-WT and Ero1α-Active 
increased oxidation within the ER lumen; 
however once again, the effect for Ero1α-WT 
did not achieve statistical significance (p = 
0.0503) whereas significance was achieved for 
Ero1α-Active (Fig. 5C).  Indeed, when 
examining the results for Ero1α-WT and Ero1α-
Active in both cell types, the relationship 
between enhancement of the ER oxidative 
environment and the extent of proinsulin-
G(B23)V secretion rescue suggested more of a 
threshold effect rather than a direct linear 
correlation (Fig. 5).  Nevertheless, as in Flp-In 
T-Rex 293 cells, these oxidizing conditions of 
the ER lumen promoted secretion rescue of 
mutant proinsulin-G(B23)V (Fig. 5D).  By 
contrast, the inactive Ero1α-Hex mutant did not 
stimulate ER luminal oxidation (not shown) and 
had only minor effects on mutant proinsulin 
export (Fig. 4).   
 As part of the canonical ER oxidation 
pathway, Ero1 is thought to transfer disulfide 
bonds to ER oxidoreductases such as PDI (29), 
which can then oxidize substrate proteins.  
However, recent studies indicate that in 
pancreatic β-cells (and 293 cells), PDI acts as an 
“unfoldase” or ER retention factor rather than as 
an oxidant of proinsulin (2,30).  To determine if 
PDI enhances or attenuates Ero1α-mediated 
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secretion rescue of mutant proinsulin, we co-
expressed hProG(B23)V-CpepMyc with PDI 
and Ero1α.  Remarkably, rescue of mutant 
proinsulin secretion in cells with increased 
expression of Ero1α-WT or Ero1α-Active was 
significantly impaired by co-expression of PDI 
(Fig. 6 lanes 3-4 and 7-8), strongly suggesting 
that Ero1α-enhanced proinsulin secretion was 
not mediated by PDI-catalyzed oxidation.  
However, co-expression of PDI had no effect in 
cells expressing the inactive Ero1α-Hex (Fig. 6 
lanes 5-6).  Thus, the activity of PDI to limit 
mutant proinsulin export depends on the 
presence of active-site cysteines in Ero1α.   
  Ero1α Does Not Augment ER Stress Induced by 
Proinsulin-G(B23)V - Expression of hyperactive 
Ero1α can activate ER stress responses (27), 
presumably caused by increased generation of 
H2O2 (31).  It was therefore of interest to know 
if Ero1-augmented oxidation in cells expressing 
proinsulin-G(B23)V triggers increased ER 
stress.  To test this in pancreatic β-cells, we co-
transfected INS1E cells with a BiP promoter-
driven luciferase (BiP-luciferase) reporter as a 
readout of ER stress signaling, and normalized 
the luciferase signal directly to the mRNA 
expression of the misfolded substrate driving the 
ER stress response (32).  Consistent with 
previous reports (8), the G(B23)V mutation 
triggered a ~2.4 fold increase in BiP-luciferase 
compared to cells expressing wt proinsulin.  
However, increased expression of Ero1α-WT 
did not augment ER stress signaling by 
proinsulin-G(B23)V; indeed it resulted in a 
statistically significant diminution of the 
G(B23)V-mediated increase in BiP-luciferase 
(Fig. 7 lane 3).  Expression of Ero1α-Active also 
tended to inhibit the G(B23)V-mediated increase 
in BiP-luciferase (Fig. 7 lane 5) whereas Ero1α-
Hex did not alleviate the ER stress response 
induced by mutant proinsulin (lane 4).  The data 
show that an increase of active Ero1 helps to 
limit ER stress generated by misfolded 
proinsulin.   
 
DISCUSSION 
 β-cells are specialized for the 
manufacture of proinsulin, yet highly 
upregulated proinsulin synthesis as occurs in 
early type 2 diabetes, promotes proinsulin 
misfolding and ER stress (4,33-37).  MIDY 
mutants offer an opportunity to study the effects 
of proinsulin misfolding on β-cell dysfunction.  
These dominant mutants associate with and 
inhibit intracellular transport of co-expressed 
wildtype proinsulin (6,9-11), and can result in 
eventual ER stress-induced β-cell death (12).  
An initial report indicated that increased 
expression of ER oxidoreductin-1 can ameliorate 
this dominant-negative effect (19).  Yet because 
oxidative stress has been linked to β-cell 
dysfunction in diabetes (38) and because Ero1 
activity includes H2O2 generation [presumed to 
be detrimental to cell health (5,7,39)], published 
studies have attempted to improve β-cell 
function and viability by decreasing Ero1 levels 
(13,14).  Although scavenging cellular reactive 
oxygen species in β-cells may have benefits 
(40), in fact decreased Ero1 levels diminish β-
cell insulin content and sensitize β-cells to ER 
stress (14).  Indeed, mice expressing the MIDY 
mutant proinsulin-C(A7)Y develop earlier and 
more severe insulin-deficient diabetes when 
even one Ero1β allele is lacking (13).  It has 
recently been argued that critical re-evaluation is 
needed of the widely held concept that Ero1-
mediated oxidation in the ER contributes to 
cellular demise (41). 
 In the current study, we have 
concentrated on proinsulin-G(B23)V as a model 
of proinsulin misfolding based on in vitro 
folding and structural biology considerations 
(8,42). Position B23 contributes to a flexible 
solvent-exposed β-turn interposed between an 
α-helix (B9-B19) and β-strand (B24-B28)  
thought necessary to prime native oxidative 
maturation, especially the initial C(B19)-C(A20) 
disulfide pairing (42).  The G(B23)V 
substitution provides a dihedral angle that limits 
flexibility of the β-turn.  Although G(B23)V 
(and selected other MIDY mutants) does not 
cause structural perturbation of the native state 
once achieved (43), this MIDY mutation is 
expected to impose a critical kinetic barrier to 
proinsulin foldability (8).  Thus, G(B23)V 
provides an ideal model with which to test 
possible therapeutic interventions.   
The enzymology underlying oxidative 
folding in the ER lumen defines an important 
frontier of pharmacology with potential 
application to diverse diseases of proteotoxicity.  
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Our work started out to confirm that increased 
expression of Ero1α attenuates the defect in 
endogenous insulin production in β-cells 
exogenously expressing mutant proinsulin-
C(A7)Y or G(B23)V (Fig. 1) — however, Ero1α 
does not at all improve the secretion of 
proinsulin-C(A7)Y itself (Fig. 2 lane 14).  Thus 
in this instance, beneficial effects of Ero1 are 
likely explained by actions on the co-expressed 
WT proinsulin partner.  Nevertheless, increased 
expression of Ero1α improves secretion of a 
subset of MIDY mutants including proinsulin-
G(B23)V even in the absence of any co-
expressed wt proinsulin (Fig. 2 lane 10).  These 
data strongly suggest a beneficial effect of Ero1 
on the mutant proinsulin itself.  We recently 
reported that secretion of proinsulin-G(B23)V is 
increased in cells co-expressing WT proinsulin 
(26).  Interestingly, many of the same MIDY 
mutants whose secretion can be enhanced by co-
expression with WT proinsulin are among those 
whose secretion can also be enhanced by 
increased expression of Ero1α.  However, Ero1α 
exerts a much stronger effect on proinsulin-
G(B23)V secretion than does co-expression of 
WT proinsulin (Fig. 2).  In fact, the two 
treatments together have an additive effect, 
implying that Ero1 and WT proinsulin may 
rescue misfolded proinsulin by distinct 
mechanisms.   
An intriguing problem is posed by the 
mechanism of secretion rescue of misfolded 
proinsulin by Ero1.  In this report, we find that 
increased Ero1 expression enhances the fraction 
of newly-synthesized proinsulin-G(B23)V 
achieving a native disulfide bonding pattern 
(Fig. 3B), and this is the form primarily 
recovered in the rescued secretion (Fig. 3C).  
Moreover, both in 293 cells and β-cells, 
increased expression of Ero1α variants that 
produce increased oxidation of the ER lumen 
(Fig. 5A, C) are accompanied by secretory 
rescue of misfolded proinsulin (Fig. 5B, D) 
whereas Ero1α-Hex, which lacks the ability to 
promote disulfide bonds via the canonical 
mechanism, exhibits markedly decreased 
proinsulin rescue (Fig. 4B, C).  From these 
results we hypothesize that rescue of proinsulin 
misfolding by Ero1 is at least in part attributed 
to improved kinetics of proinsulin oxidative 
folding, especially the C(B19)-C(A20) disulfide 
pairing.  However, ER-based oxidation remains 
poorly understood.  The best-studied Ero1 
substrate is PDI, and until recently it was 
assumed that PDI shuttles disulfide bonds to 
nascent proinsulin.  However, new evidence has 
suggested that PDI actually retards insulin 
production in β-cells and limits proinsulin 
intracellular transport (2,30).  Herein we find 
that co-transfection of PDI attenuates the rescue 
of misfolded proinsulin provided by Ero1α-WT 
or Ero1α-Active, whereas it had no effect in 
cells expressing the catalytically inactive Ero1α-
Hex (Fig. 6).  These data suggest that PDI either: 
a) inhibits the enzymatic activity of Ero1α 
(which is unlikely), b) competes with other ER 
oxidoreductases involved in proinsulin folding, 
or c) acts directly on proinsulin in a manner that 
actually limits proinsulin folding and transport.  
Indeed, a direct physical interaction between 
PDI and proinsulin in the ER has been 
demonstrated (2).  Altogether, the current data 
clearly support the conclusion that oxidative 
folding of proinsulin, promoted by Ero1, is not 
mediated by PDI.  Nevertheless, our results 
suggest the possibility — counter to current 
thinking (40) — that augmenting the oxidative 
capacity of the ER in β-cells may be a 
reasonable therapeutic strategy for the treatment 
of proinsulin misfolding that occurs when its 
synthesis is excessively upregulated (3,4), such 
as in early type 2 diabetes.  Accordingly, we 
found that both Ero1α-WT and Ero1α-Active 
limited the ER stress response to proinsulin-
G(B23)V in β-cells whereas Ero1α-Hex was 
without effect (Fig. 7).  These data provide sup-
port for the notion that Ero1-mediated oxidation 
of the ER lumen may be beneficial to cells (41), 
especially in light of recent findings that H2O2 
generated by Ero1 may be consumed by con-
current activity of other gene products (44,45).   
 While promotion of oxidative folding of 
molecules with kinetic impairment of the 
proinsulin folding pathway is a critical 
contribution of Ero1, we note that cells 
expressing Ero1α-Hex also showed a modest 
fractional enhancement of proinsulin secretion 
(Fig. 4C).  Likewise, we did not observe a 
precise correlation between the fractional 
increase of ER luminal oxidation and the extent 
of proinsulin-G(B23)V secretion rescue (Fig. 5).  
Together, these data raise the possibility that 
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Ero1α has additional activities or protein 
partners that may influence the folding and 
secretion of proinsulin.  Further investigation is 
needed to explore the magnitude of these effects 
on secretory protein substrates and to understand 
the underlying mechanism and significance of 
Ero1α oxidative and non-oxidative activities.  
Ultimately, we believe that ER-targeted 
therapies, such as that presented as a proof of 
principle in this report, offer a novel opportunity 
to intervene in the pathogenesis of beta cell 
dysfunction in type 2 diabetes mellitus.      
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FIGURE LEGENDS 
 
FIGURE 1.  Ero1α rescues wild type proinsulin in the presence of MIDY mutants.  INS1E cells were 
triply transfected with plasmids expressing WT hPro-CpepMyc, the indicated mouse proinsulin (mPro) 
mutants, plus Ero1α or empty vector.  At 48 h after transfection, the media were changed for a further 
overnight collection.  Cells were lysed in RIPA buffer, and human proinsulin secretion was measured by 
human proinsulin specific RIA normalized to total cellular protein content.  Data represent mean ± S.E.M. 
of three independent transfections.  *p < 0.05 vs. cells co-expressing WT mPro.  †p < 0.05 vs. cells 
untransfected with Ero1α.   
 
FIGURE 2.  Ero1α rescues secretion of MIDY mutants.  293T cells were transiently co-transfected with 
plasmids expressing the indicated human proinsulin mutants and Ero1α or empty vector (EV).  At 24 h 
post-transfection, media were collected overnight and the cells lysed in RIPA buffer.  Upper panel: 
Proinsulin secretion was measured by human proinsulin specific RIA, normalized to total cellular protein 
content.  Data represent mean ± range of two independent transfections and is expressed as fold increase 
of secretion from cells co-transfected with Ero1α over secretion over cells co-transfected with EV.  Lower 
panels: Immunoblots of cell lysates using anti-Ero1α antibodies show the level of total Ero1α expression 
after Ero1 transfection (lanes 2-14) compared to EV (lane 1 shows the cellular level found in all EV 
transfections), with α-tubulin used as a loading control.  Noncontiguous lanes from the same gel are 
shown (white line separators).   
 
FIGURE 3. Ero1α enhances folding and secretion of the proinsulin-G(B23)V mutant. (A) 293T cells 
were triply co-transfected with hProG(B23)V-CpepMyc ± wildtype mouse proinsulin (mProWT) ± 
Ero1α.  At 24 h post-transfection, cell culture media were collected overnight, and cells were lysed in 
RIPA buffer.  (A) Human proinsulin (hPro) secretion was measured by human-specific RIA, normalized 
to total cellular protein content.  Data represents mean ± S.E.M. of three independent transfections, 
expressed as fold increase in secretion compared to cells transfected with hProG(B23)V-CpepMyc alone.  
*p < 0.05 vs. the first bar; †p < 0.05 vs. the second bar.  Between the third and fourth bars, p = 0.08.  (B) 
293T cells co-transfected with WT or G(B23)V hPro-CpepMyc ± Ero1α, as indicated, were pulse-labeled 
with 35S-amino acids for 30 min.  After washing cells in ice cold PBS containing 20 mM NEM for 5 min, 
cells were lysed in RIPA containing 2 mM NEM.  After immunoprecipitation with anti-Myc antibodies, 
samples were analyzed by reducing or nonreducing tris-tricine-urea-SDS-PAGE and autoradiography.  
The nonreduced lane 3 is a longer exposure of the sample to allow direct examination of band intensities 
relative to lane 2.  Data represent mean ± S.E.M. of densitometric quantification of native proinsulin band 
intensity over total proinsulin intensity. N = 4, *p < 0.05 vs. cells untransfected with Ero1α.  
Noncontiguous lanes from the same gel were spliced together (white line separators).  (C).   293T cells 
co-transfected with WT or mutant proinsulin as shown plus empty vector (EV) or Ero1α and pulse-
labeled as in B) were chased for 2 h prior to cell lysis.  Both cell lysates and media were analyzed by 
immunoprecipitation, nonreducing tris-tricine-urea-SDS-PAGE, and autoradiography.  Noncontiguous 
lanes from the same gel were spliced together (white space separator, with increased exposure of the 
hProG(B23)V sample to detect minor bands in the cell lysate).  Asterisks denote non-native proinsulin 
disulfide isomers of unknown identity collected in the medium, one of which is increased from cells 
expressing hProG(B23)V.  Increased secretion of native proinsulin isomer from cells co-expressing 
hProG(B23)V plus Ero1α was observed in each of four independent experiments.   
 
FIGURE 4.  The ability of different Ero1α variants to rescue export of mutant proinsulin-G(B23)V.  (A) 
Schematic representation of the Ero1α active sites (C94-C99, and C394-C397) and regulatory cysteines 
(C104-C131) in WT Ero1α, Ero1α-Hex, and Ero1α-Active.  (B) 293T cells were co-transfected with the 
indicated hPro-CpepMyc and Ero1αMyc6His plasmids.  At 24 h post-transfection, cell culture media was 
collected overnight, and cells were lysed in RIPA buffer.  Secretion of hPro-CpepMyc and cellular 
content of hPro-CpepMyc and Ero1αMyc6His were measured by Western blot analysis using anti-Myc 
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antibodies.  Gel loading was normalized to total cellular protein content.  (C) Data represent 
densitometric quantification of bands from B), expressed as media over total (cell + media) band 
intensity, n=3.  *p < 0.05 vs. cells lacking any Ero1αMyc6His. †p < 0.05 vs. cells co-expressing WT 
Ero1αMyc6His.   
 
FIGURE 5. Hyperoxidation of the ER lumen promotes export of mutant proinsulin-G(B23)V. (A) Flp-In 
T-Rex-293 cells inducibly expressing Ero1αMyc6His-WT, or Ero1αMyc6His-Active were stably 
transfected to express the HyPerER sensor and treated with or without 1 µg/mL doxycycline (Dox) for 24 
h. Fluorescence spectra of HyPerER sensor in the cells were obtained with appropriate controls (see 
Experimental Procedures).  The Dox-induced fold-increase in the 500/420 nm fluorescence ratio along 
with 95% confidence intervals (n ≥ 3) is shown; *p < 0.05.  (B) Flp-In T-Rex-293 cells were transiently 
transfected with hProG(B23)V-CpepMyc. At 24 h post-transfection, cells were split into separate wells 
and treated with or without Dox as in panel A.  Cell culture media were then collected overnight.  The 
Dox-induced fold-increase of proinsulin secretion (measured by insulin RIA, normalized to total cellular 
protein content) is shown; *p < 0.05 vs. –Dox cells.  A stable clone of Flp-In T-Rex-293 cells inducibly 
expressing only empty vector (EV) is also included; panels A and B represent data from three 
independent experiments. (C) INS1E cells transiently expressing the Grx1-roGFP1-iEER oxidation 
reporter and either empty vector (EV) or the indicated Ero1αMyc6His variant were analyzed by 
nonreducing SDS-PAGE and Western blot to determine the percentage of Grx1-roGFP1-iEER oxidation; 
*p < 0.05 vs. EV.  (D) INS1E cells transiently co-transfected with hProG(B23)V-CpepMyc and empty 
vector (EV) or the indicated Ero1αMyc6His variant.  At 24 h post-transfection, cell culture media were 
collected overnight, and cells were lysed; proinsulin secretion was measured by human proinsulin specific 
RIA normalized to total cellular protein content.  The data in panels C and D represent mean ± S.E.M. 
from 3-4 independent experiments; *p < 0.05 vs. EV.   
 
FIGURE 6. PDI antagonizes the ability of Ero1α to promote proinsulin-G(B23)V secretion.  293T cells 
were triply transfected with hProG(B23)V-CpepMyc with the indicated Ero1αMyc6His mutants with or 
without PDI-flag.  At 24 h post-transfection, cell culture media were collected overnight, and cells were 
lysed in RIPA buffer.  Proinsulin secretion was detected by insulin RIA, normalized to total cellular 
protein content.  Data represent mean ± S.E.M. from 4 independent experiments. *p < 0.05 vs. control 
cells lacking PDI-flag.  Ero1αMyc6His was confirmed by anti-Myc immunoblot, with α-Tubulin as a gel 
loading control.   
 
FIGURE 7.  Ero1α decreases ER stress activated by proinsulin-G(B23)V. INS1E cells were triply 
transfected with plasmids expressing BiP-promoter driven luciferase and the indicated hPro-CpepMyc 
and Ero1αMyc6His mutants.  Transfected cells were split into 3 separate wells, and 48 h after transfection 
cells were lysed.  Lysates were either used to measure luciferase signal by luminometer, human proinsulin 
mRNA by RT-qPCR, or hPro-CpepMyc and Ero1αMyc6His content by anti-Myc immunoblot with α-
Tubulin as a loading control.  Data represent mean ± S.E.M. of 5 independent experiments. *p < 0.05 
compared to cells expressing hProG(B23)V-CpepMyc without Ero1αMyc6His, expressed as fold increase 
of luciferase signal over human insulin mRNA compared to cells expressing WT proinsulin.  
Noncontiguous lanes from the same gel were spliced together (white line separators).   
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